Apolipoprotein A-1 in the treatment of acute myocardial infarction

Haowen Xue

doi:10.1117/12.2669857

24 March 2023 Apolipoprotein A-1 in the treatment of acute myocardial infarction

Haowen Xue

Proceedings Volume 12611, Second International Conference on Biological Engineering and Medical Science (ICBioMed 2022); 126114A (2023) https://doi.org/10.1117/12.2669857
Event: International Conference on Biological Engineering and Medical Science (ICBioMed2022), 2022, Oxford, United Kingdom

Abstract

With the gradual rejuvenation and rising popularity of acute myocardial infarction, more and more researchers have begun to investigate novel treatments for this disease. The treatment plan for continuing to increase high-density cholesterol based on apolipoprotein A-1 is gradually recognized by more and more people because of its theoretical and clinical practicability. However, there are relatively fewer experiments demonstrating the viability of apolipoprotein A-1 in clinical treatment compared to aspirin, ticlopidine, clopidogrel, and PTCA (percutaneous transluminal coronary angioplasty), which are mature technologies, and the summary of various clinical data is also far from sufficient. Therefore, apolipoprotein A-1 therapy is not widely used in the treatment of acute myocardial infarction yet. To fill this gap, this review will state the important clinical trials of apolipoprotein A-1 in treating acute myocardial infarction. in recent decades, summarize its clinical information, and analyze its proof of the feasibility for apolipoprotein therapy. Additionally, this review will assess the benefits and drawbacks of apolipoprotein A-1 therapy and currently available mature therapies (such as aspirin, ticlopidine and clopidogrel, PTCA). Therefore, it highlights the positive direction of apolipoprotein A-1 treatment and approaches in upcoming clinical experiments, assisting in apolipoprotein A-1 treatment's future rise to popularity.

Citation Download Citation

Haowen Xue "Apolipoprotein A-1 in the treatment of acute myocardial infarction", Proc. SPIE 12611, Second International Conference on Biological Engineering and Medical Science (ICBioMed 2022), 126114A (24 March 2023); https://doi.org/10.1117/12.2669857

ACCESS THE FULL ARTICLE

INSTITUTIONAL
Select your institution to access the SPIE Digital Library.

SELECT YOUR INSTITUTION

PERSONAL
Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.

PERSONAL SIGN IN

No SPIE Account? Create one

PURCHASE THIS CONTENT

SUBSCRIBE TO DIGITAL LIBRARY

50 downloads per 1-year subscription

Members: $195

Non-members: $335 ADD TO CART

25 downloads per 1 - year subscription

Members: $145

Non-members: $250 ADD TO CART

PURCHASE SINGLE ARTICLE

Includes PDF, HTML & Video, when available

Members: $17.00

Non-members: $21.00 ADD TO CART

PROCEEDINGS
7 PAGES

DOWNLOAD PAPER SAVE TO MY LIBRARY

GET CITATION

RIGHTS & PERMISSIONS

Get copyright permission Get copyright permission on Copyright Marketplace

KEYWORDS

Arteries

Heart

Atherosclerosis

Cardiovascular disorders

Proteins

Arrhythmia

Blood

Show All Keywords

Keywords/Phrases

Search In:

Publication Years